$144 Million is the total value of GREAT POINT PARTNERS LLC's 32 reported holdings in Q3 2013. The portfolio turnover from Q2 2013 to Q3 2013 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HPTX | New | HYPERION THERAPEUTICS INC | $21,450,000 | – | 820,906 | +100.0% | 14.88% | – |
| FURX | New | FURIEX PHARMACEUTICAL INC | $15,368,000 | – | 349,356 | +100.0% | 10.66% | – |
| AMBI | New | AMBIT BIOSCIENCES CORP | $13,693,000 | – | 883,459 | +100.0% | 9.50% | – |
| SSH | New | SUNSHINE HEART INC | $12,598,000 | – | 1,087,952 | +100.0% | 8.74% | – |
| GERN | New | GERON CORP | $8,315,000 | – | 2,482,185 | +100.0% | 5.77% | – |
| PTIE | New | PAIN THERAPEUTICS INC | $7,918,000 | – | 2,910,849 | +100.0% | 5.49% | – |
| GENTY | New | GENTIUM S P Asponsored adr | $6,098,000 | – | 224,767 | +100.0% | 4.23% | – |
| SPHS | New | SOPHIRIS BIO INC | $5,991,000 | – | 1,280,000 | +100.0% | 4.16% | – |
| NSPH | New | NANOSPHERE INC | $5,000,000 | – | 2,500,000 | +100.0% | 3.47% | – |
| DRTX | New | DURATA THERAPEUTICS INC | $4,596,000 | – | 508,472 | +100.0% | 3.19% | – |
| HTWR | New | HEARTWARE INTL INC | $4,392,000 | – | 60,000 | +100.0% | 3.05% | – |
| BIOD | New | BIODEL INC | $4,204,000 | – | 1,334,483 | +100.0% | 2.92% | – |
| TRIB | New | TRINITY BIOTECH PLCspon adr new | $4,114,000 | – | 189,071 | +100.0% | 2.85% | – |
| STRM | New | STREAMLINE HEALTH SOLUTIONS | $3,617,000 | – | 475,878 | +100.0% | 2.51% | – |
| 5100PS | New | VOLCANO CORPORATION | $3,413,000 | – | 142,500 | +100.0% | 2.37% | – |
| New | AMARIN CORP PLCcall | $3,160,000 | – | 500,000 | +100.0% | 2.19% | – | |
| NDZ | New | NORDION INC | $2,588,000 | – | 299,902 | +100.0% | 1.80% | – |
| OGXI | New | ONCOGENEX PHARMACEUTICAL INC | $2,454,000 | – | 264,686 | +100.0% | 1.70% | – |
| MSTX | New | MAST THERAPEUTICS INC | $2,390,000 | – | 5,442,400 | +100.0% | 1.66% | – |
| GIVN | New | GIVEN IMAGING | $2,269,000 | – | 118,000 | +100.0% | 1.57% | – |
| RTIX | New | RTI SURGICAL INC. | $2,266,000 | – | 606,015 | +100.0% | 1.57% | – |
| PLX | New | PROTALIX BIOTHERAPEUTICS INC | $1,808,000 | – | 399,007 | +100.0% | 1.25% | – |
| MEIP | New | MEI PHARMA INC | $1,774,000 | – | 157,661 | +100.0% | 1.23% | – |
| TXMD | New | THERAPEUTICSMD INC | $1,221,000 | – | 416,667 | +100.0% | 0.85% | – |
| ARQL | New | ARQULE INC | $871,000 | – | 373,926 | +100.0% | 0.60% | – |
| AVNR | New | AVANIR PHARMACEUTICALS INCcall | $846,000 | – | 200,000 | +100.0% | 0.59% | – |
| PTX | New | PERNIX THERAPEUTICS HLDGS INC | $807,000 | – | 296,811 | +100.0% | 0.56% | – |
| HZNP | New | HORIZON PHARMA INC | $335,000 | – | 100,000 | +100.0% | 0.23% | – |
| New | ALIMERA SCIENCES INCcall | $279,000 | – | 74,300 | +100.0% | 0.19% | – | |
| PTN | New | PALATIN TECHNOLOGIES INC | $133,000 | – | 192,992 | +100.0% | 0.09% | – |
| GTXI | New | GTX INC DELput | $117,000 | – | 57,700 | +100.0% | 0.08% | – |
| WMGIZ | New | WRIGHT MED GROUP INCright 03/01/2019 | $41,000 | – | 116,600 | +100.0% | 0.03% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2013-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTNS, INC CMN | 25 | Q3 2019 | 2.5% |
| IOVANCE BIOTHERAPEUTICS, INC. CMN | 16 | Q1 2021 | 14.3% |
| ZOGENIX INC CMN | 16 | Q4 2019 | 8.8% |
| PTC THERAPEUTICS, INC. CMN | 16 | Q3 2023 | 9.9% |
| EXELIXIS, INC | 16 | Q1 2022 | 7.5% |
| SAGE THERAPEUTICS, INC CMN | 15 | Q3 2021 | 10.8% |
| CYTOKINETICS INC | 15 | Q3 2023 | 5.8% |
| ACADIA PHARMACEUTICALS, INC. | 14 | Q1 2021 | 8.8% |
| ACCELERON PHARMA INC CMN | 14 | Q2 2020 | 8.2% |
| CONNECTURE INC | 13 | Q4 2017 | 25.1% |
View GREAT POINT PARTNERS LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| 89bio, Inc. | February 14, 2023 | 700,000 | 1.4% |
| KalVista Pharmaceuticals, Inc. | February 14, 2023 | 1,055,801 | 3.1% |
| Avalo Therapeutics, Inc. | February 13, 2023 | 974,639 | 7.1% |
| InflaRx N.V.Sold out | February 14, 2022 | 0 | 0.0% |
| ABEONA THERAPEUTICS INC.Sold out | February 16, 2021 | 0 | 0.0% |
| CONSTELLATION PHARMACEUTICALS INC | February 16, 2021 | 1,024,800 | 2.2% |
| GERON CORP | February 16, 2021 | 12,754,228 | 4.0% |
| Millendo Therapeutics, Inc. | February 16, 2021 | 270,000 | 1.4% |
| NextCure, Inc.Sold out | February 16, 2021 | 0 | 0.0% |
| PROTHENA CORP PUBLIC LTD CO | February 16, 2021 | 977,647 | 2.4% |
View GREAT POINT PARTNERS LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-08 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View GREAT POINT PARTNERS LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.